What diseases is Quizartinib mainly used to treat? What are its indications?

Quizartinib is an oral FLT3 inhibitor, mainly used to treat acute myeloid leukemia (AML), especially Patients with FLT3-ITD (Fms-like tyrosine kinase3 internal tandem repeat mutations). The FLT3-ITD mutation is a genetic variation commonly found in AML patients and is often associated with rapid disease progression, high risk of relapse, and poor prognosis. Quizartinib blocks the proliferation signals of leukemia cells by inhibiting the activity of the FLT3 receptor, thereby helping to delay disease progression and improve survival.

In treatment, quizartinib is usually used in combination with standard chemotherapy or as single-agent maintenance therapy in patients with relapsed/refractory AML. According to clinical trial results, for patients with FLT3-ITD mutated AML who have relapsed after standard treatment or who are refractory to treatment, quizartinib can significantly improve the complete response rate and prolong the time without disease progression. Treatment options for this population were originally limited, and the emergence of quizartinib has brought them new hope.

In addition to patients with relapsed or refractory AML, quizartinib is also being studied in the induction and consolidation phases of patients with previously untreated AML, particularly in the setting of FLT3 mutations. By combining with other drugs such as cytarabine and daunorubicin, the remission rate can be improved in the early stage of treatment and create better conditions for subsequent hematopoietic stem cell transplantation. Its targeting mechanism determines that its indications are relatively precise, mainly focusing on FLT3 mutant leukemia.

It should be noted that the current approval status of Quizartinib for indications in different countries and regions may vary. It is not yet available in some areas, and patients may need to obtain it through overseas drug channels. At the same time, regular monitoring of electrocardiogram and electrolyte levels is required when using this drug to prevent side effects such as prolonged QT interval. Overall, quizartinib provides a more targeted treatment option for patients with FLT3-ITD mutated AML, which is of great significance in the field of precision medicine.

Reference materials:https://go.drugbank.com/drugs/DB12874